SK Biopharmaceuticals

Pharma

SK settles with MSN over generic of seizure med Xcopri: reports

SK has struck a settlement with generics manufacturer MSN, which will allow the Korean company to extend its market exclusivity beyond 2032 for Xcopri.

Kevin Dunleavy Aug 19, 2026 11:21am

BMS JV sale, biotech debuts, possible deals—Fierce Pharma Asia

Sep 19, 2025 8:36am

SK eyes Xcopri expansion with phase 3 win in new seizure type

Sep 17, 2025 11:32am

Hengrui, Sanofi and Aslan—Fierce Pharma Asia

Jul 19, 2024 9:48am

SK Biotek earmarks $35M to expand its Irish API production plant

Jun 16, 2022 9:20am

Takeda, Merck, SK Biopharm and more—Fierce Pharma Asia

Nov 12, 2021 9:20am